|Table of Contents|

A Meta-analysis of the clinical efficacy and safety of elemene combined cis-platinum pleural perfusion for the treatment of malignant pleural effusion

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 06
Page:
879-884
Research Field:
Publishing date:

Info

Title:
A Meta-analysis of the clinical efficacy and safety of elemene combined cis-platinum pleural perfusion for the treatment of malignant pleural effusion
Author(s):
Fan Yali12Dong Ya12Zhao Yuling12Yu Jun3Liu An1Li Jianying1
1.Department of Respiratory Disease,Xi'an Central Hospital Affiliated to Medical College of Xi'an Jiaotong University,Shaanxi Xi'an 710003,China;2.Medical College of Yan'an University,Shaanxi Yan'an 716000,China;3.Department of Emergency,Xi'an Central Hos
Keywords:
elemene emulsioncis-platinummalignant pleural effusionMeta-analysis
PACS:
R730.53
DOI:
10.3969/j.issn.1672-4992.2018.06.016
Abstract:
Objective:To systematically evaluate the clinical efficacy and safety of elemene combined cis-platinum pleural perfusion for the treatment of malignant pleural effusion.Methods:"Elemene emulsion,cis-platinum,malignant pleural effusion,Meta-analysis"were the key words,and the following databases were retrieved by computer:Pubmed,CNKI,Wanfang data base,FMRS and so on.To collecte the radomized controlled trials about elemene combined cis-platinum pleural perfusion for the treatment of malignant pleural effusion(MPE),and RevMan 5.3 software was used for Meta-analysis.Results:Six RCTs were adopted,and included 463 patients of MPE.The method of radomized control was used by all these studies,the result was showed by the Meta-analysis.The effective rate of elemene emulsion combined cis-platinum pleural perfusion is better than the simple cis-platinum for the treatment of malignant pleural effusion,there was a significant difference(P<0.000 1),and did not increase the adverse of drug reactions.Conclusion:In the treatment of MPE,elemene emulsion combined cis-platinum pleural perfusion is better than the simple cis-platium,and had lower rate of adverse reactions.

References:

[1]Roberts ME,Neville E,Berrisford RG,et al.Management of a malignant pleural effusion:British Thoracic Society Pleural Disease Guideline 2010[J].Thorax,2010,65(Suppl 2):ii32.
[2]Haas AR,Sterman DH,Musani AI.Malignant pleural effusions:Management options with consideration of coding,billing,and a decision approach[J].Chest,2007,132(3):1036-1041.
[3]Yang M,Peng L.Treatment and progress of malignant pleural effusion[J].International Journal of Breathing,2017,37(4):302-305.[杨梅,彭丽.恶性胸腔积液治疗方法及进展[J].国际呼吸杂志,2017,37(4):302-305.]
[4]Li QQ,Wang G,Zhang M,et al.Beta-Elemene,a novel plant-derived antineoplastic agent,increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis[J].Oncology Reports,2009,22(1):161.
[5]Chi YM.The clinical observation of central venous catheter pleural lien and elemene and cis-platinum injection for the treatment of malignant pleural effusion[J].Journal of Clinical Lung,2012,17(8):1528-1530.[迟玉敏.中心静脉导管胸腔留置并榄香烯及顺铂注入治疗恶性胸水疗效观察[J].临床肺科杂志,2012,17(8):1528-1530.]
[6]Dong KX,Wang SX.Recent therapeutic observation of pleural cavity catheter drainage and perfusion elemene combined cisplatinum for the treatment of malignant pleural effusion of lung cancer[J].Chinese Journal of Clinical Doctors,2016,44(10):60-62.[董可新,王书学.胸膜腔置管引流并灌注榄香烯联合顺铂治疗肺癌恶性胸腔积液的近期疗效观察[J].中国临床医生杂志,2016,44(10):60-62.]
[7]Liu C,Zhang HY,Jia ZL,et al.The clinical observation of elemene combined cisplatin chest injection for the treatment of malignant hydrothorax[J].Modern Chinese and Western Medicine Journal,2011,20(12):1496-1497.[刘畅,张宏艳,贾志凌,等.榄香烯注射液联合顺铂胸腔注射治疗恶性胸水临床观察[J].现代中西医结合杂志,2011,20(12):1496-1497.]
[8]Liu Z.Curative effect analysis of PLF joint elemene injection for the treatment of malignant pleural effusion[J].Journal of Clinical Medical Research and Practice,2016,1(19):51-52.[刘赞.PLF联合榄香烯注射液治疗恶性胸腔积液的疗效分析[J].临床医学研究与实践,2016,1(19):51-52.]
[9]Shi FF,Dong LJ.The clinical observation of elemene and cisplatin pleural perfusion combined thermal therapy in the treatment of malignant pleural effusion[J].Journal of Clinical Medicine,2015,19(s1):89-91.[侍方方,董丽均.榄香烯和顺铂胸腔灌注联合热疗治疗恶性胸腔积液的临床观察[J].实用临床医药杂志,2015,19(s1):89-91.]
[10]Wang LD,Ding D.Cinical curative effect observation of elemene combined with small dose of cisplatin chest injection for the treatment of malignant pleural effusion in patients with lung cancer[J].Journal of Clinical Research,2012,29(8):1524-1525.[王丽丹,丁达.榄香烯乳联合小剂量顺铂胸腔注射治疗肺癌患者恶性胸腔积液临床疗效观察[J].医学临床研究,2012,29(8):1524-1525.]
[11]Jiang L,Li P,Gong Z,et al.Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin[J].Anticancer Research,2016,36(3):1313.
[12]Yang WL,Fu XH,Gu Y.Treatment progress of malignant pleural effusion[J].Medical Review,2017,23(5):971-975.[杨婉玲,付秀华,顾岩.恶性胸腔积液的治疗进展[J].医学综述,2017,23(5):971-975.]
[13]Gao S,Zhao WS,Fu Q,et al.The curative effect observation of elemene emulsion combined cisplatinum in the treatment of malignant pleural effusion[J].Journal of Hebei Medical University,2010,31(12):1479-1481.[高甦,赵文硕,富琦,等.榄香烯乳联合顺铂治疗恶性胸腔积液的疗效观察[J].河北医科大学学报,2010,31(12):1479-1481.]
[14]Yao Ruipin,Yu Chaoqin,Zhang Danying,et al.Intravitoneal injection of the single drug of elemene to relieve the malignant effusion of ovarian cancer(12 cases)[J].Modern Oncology,2017,25(14):2288-2290.[姚睿嫔,俞超芹,张丹英,等.榄香烯乳单药腔内注射缓解难治性卵巢癌恶性胸腹水(附12例)[J].现代肿瘤医学,2017,25(14):2288-2290.]
[15]Chen SM,Deng TH,Xie H,et al.Clinical observation on the treatment of malignant pleural effusion in patients with non-small cell lung cancer in the thoracic perfusion of traditional Chinese medicine[J].Journal of Guangxi University of Chinese Medicine,2017,20(1):9-11.[陈四明,邓天好,谢辉,等.中药制剂胸腔灌注治疗非小细胞肺癌恶性胸腔积液临床观察[J].广西中医药大学学报,2017,20(1):9-11.]
[16]Wang Y,Ji HM,Xie JH,et al.The curative effect observation of elemene emulsion combined cisplatinum chest injection for the treatment of malignant pleural effusion[J].Journal of Traffic Medicine,2016,30(4):322-323.[王彧,吉浩明,谢锦华,等.榄香烯乳联合顺铂胸腔灌注治疗恶性胸腔积液效果观察[J].交通医学,2016,30(4):322-323.]

Memo

Memo:
西安市科技计划项目[编号:2016047SF/YX03(3)]
Last Update: 2018-01-29